XELJANZ / XELJANZ XR (tofacitinib) Overdosage

Medical Information
Canada
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Canadian Healthcare Professionals. Would you like to proceed?

There is no experience with overdose of XELJANZ/XELJANZ XR (tofacitinib). There is no specific antidote for overdose with XELJANZ/XELJANZ XR. Treatment should be symptomatic and supportive. In case of an overdose, it is recommended that the patient be monitored for signs and symptoms of adverse reactions. Patients who develop adverse reactions should receive appropriate treatment.

Pharmacokinetic data up to and including a single dose of 100 mg in healthy volunteers indicates that more than 95% of the administered dose is expected to be eliminated within 24 hours.

For management of a suspected drug overdose, contact your regional Poison Control Centre.